53. Sjogren syndrome Clinical trials / Disease details
Clinical trials : 283 / Drugs : 320 - (DrugBank : 101) / Drug target genes : 56 - Drug target pathways : 181
Showing 1 to 10 of 283 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-jRCT2031210484 | 28/02/2022 | 14/12/2021 | A Study of Nipocalimab in Adults with Primary Sjogren'sSyndrome (pSS) | A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome(pSS) A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety ... | Sjogren's Syndrome | Placebo Placebo infusion will be administered intravenously. Nipocalimab Nipocalimab dose 1 and dose 2 infusions will be administered intravenously. Standard of Care Treatment Standard of care treatment including ophthalmic drops, artificial tears and saliva, punctum plugs, and secretagogues, and/or one immunomodulator with or without low-dose glucocorticosteroids will be administered topically/orally. Placebo Placebo infusion will be administered intravenously. Nipocalimab Nipocalimabdose 1 and dose 2 i ... | Numaguchi Hirotaka | NULL | Pending | >= 18age old | <= 65age old | Both | 150 | Phase 2 | Germany;Spain;Italy;Netherlands;Poland;Portugal;United States Of America;France;Taiwan;Japan |
| 2 | EUCTR2021-000665-32-NL (EUCTR) | 16/02/2022 | 21/10/2021 | A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) | Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of ... | Primary Sjogren's Syndrome MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Primary Sjogren's Syndrome MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogre ... | Product Name: Nipocalimab Product Code: M281 INN or Proposed INN: nipocalimab Other descriptive name: JNJ-80202135 Product Name: Nipocalimab Product Code: M281 INN or Proposed INN: nipocalimab Other descriptive name: J ... | Janssen-Cilag International NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | Portugal;France;United States;Taiwan;Spain;Poland;Germany;Netherlands;Italy;Japan | ||
| 3 | NCT05124925 (ClinicalTrials.gov) | January 26, 2022 | 8/11/2021 | Biopsy Study in Patients With Sjogren's Disease to Investigate Safety and Effect of Ianalumab on Salivary Glands Biopsy Study in Patients With Sjogren's Disease to Investigate Safety and Effect of Ianalumab on Sal ... | An Open-label, Non-randomized, Biopsy-based Mechanistic Study on Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Ianalumab in Patients With Sjögren's Syndrome An Open-label, Non-randomized, Biopsy-based Mechanistic Study on Efficacy, Pharmacokinetics, Pharmac ... | Sjogren Syndrome | Biological: Ianalumab | Novartis Pharmaceuticals | NULL | Not yet recruiting | 18 Years | N/A | All | 24 | Phase 2 | NULL |
| 4 | NCT05113004 (ClinicalTrials.gov) | January 5, 2022 | 2/11/2021 | New Clinical End-points in Patients With Primary Sjögren's Syndrome | NEw Clinical Endpoints in Patients With Primary Sjögren's Syndrome (pSS): an Interventional Trial Based on stratifYing Patients NEw Clinical Endpoints in Patients With Primary Sjögren's Syndrome(pSS): an Interventional Trial Bas ... | Primary Sjögren's Syndrome (pSS) | Drug: Hydroxychloroquine 400mg/d;Drug: Leflunomide 20mg/d;Drug: Mycophenolate mofetil 2000mg/d;Drug: Placebo of Hydroxychloroquine 400mg/d;Drug: Placebo of Leflunomide 20mg/d;Drug: Placebo of Mycophenolate mofetil 2000mg/d Drug: Hydroxychloroquine400mg/d;Drug: Leflunomide20mg/d;Drug: Mycophenolatemofetil2000mg/d;Drug: Pla ... | Assistance Publique - Hôpitaux de Paris | NULL | Not yet recruiting | 18 Years | N/A | All | 300 | Phase 2 | NULL |
| 5 | EUCTR2021-003749-39-IT (EUCTR) | 15/12/2021 | 15/10/2021 | A 4 week, Phase III, multicenter, double-masked, study to evaluate safety and efficacy of Oxervate® (cenegermin) 20 mcg/mL ophthalmic solution in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. A 4 week, Phase III, multicenter, double-masked, study to evaluate safety and efficacy of Oxervate® ... | A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and efficacy of Cenegermin (Oxervate®) 20 mcg/mL ophthalmic solution versus vehicle, in patients with severe Sjogren’s dry eye disease under treatment with Cyclosporine A. - NGF0221 A 4 week, Phase III, multicenter, double-masked, vehicle-controlled study to evaluate safety and eff ... | Severe Sjogren’s dry eye disease MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: Sjogren's syndrome;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders;Therapeutic area: Diseases [C] - Eye Diseases [C11] Severe Sjogren’s dry eye disease MedDRA version: 21.0;Level: PT;Classification code 10040767;Term: S ... | Trade Name: Oxervate Product Name: OXERVATE Product Code: [Recombinant Human Nerve Growth Factor (rhNGF)] INN or Proposed INN: Cenegermin Other descriptive name: Recombinant form of human nerve growth factor produced in Escherichia Coli. Trade Name: Oxervate Product Name: OXERVATE Product Code: [Recombinant Human Nerve Growth Factor (rhNG ... | DOMPé FARMACEUTICI S.P.A. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 48 | Phase 3 | United States;Italy | ||
| 6 | NCT04563195 (ClinicalTrials.gov) | December 1, 2021 | 12/9/2020 | BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome | BAFF/IL-17 Bispecific Antibody Treatment in Subjects With Primary Sjogren's Syndrome | Primary Sjogren's Syndrome | Drug: tibulizumab (LY3090106) | Matthew C. Baker | NULL | Not yet recruiting | 18 Years | 85 Years | All | 12 | Phase 2/Phase 3 | United States |
| 7 | NCT04988087 (ClinicalTrials.gov) | November 30, 2021 | 26/7/2021 | A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's Syndrome (SjS) or Mixed Connective Tissue Disease (MCTD) A Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjogren's S ... | A Multi-center, Randomized, Participant- and Investigator- Blinded, Placebo-controlled, Parallel Group Basket Study to Evaluate the Safety, Tolerability and Efficacy of MHV370 in Participants With Sjögren's Syndrome or Mixed Connective Tissue Disease A Multi-center, Randomized, Participant- and Investigator- Blinded, Placebo-controlled, Parallel Gro ... | Sjogren Syndrome;Mixed Connective Tissue Disease | Drug: MHV370;Drug: Placebo | Novartis Pharmaceuticals | NULL | Recruiting | 18 Years | 75 Years | All | 60 | Phase 2 | China;Germany;Hungary;Spain;United Kingdom |
| 8 | NCT05087589 (ClinicalTrials.gov) | November 20, 2021 | 8/10/2021 | Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's Syndrome Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjogren's S ... | Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjögren's Syndrome:a Prospective Observational Study Efficacy, Safety and Immunological Evaluation of Tofacitinib in the Treatment of Primary Sjögren's S ... | Primary Sjögren's Syndrome | Drug: Tofacitinib | Peking University People's Hospital | NULL | Recruiting | 18 Years | N/A | All | 10 | Phase 2 | China |
| 9 | NCT03953703 (ClinicalTrials.gov) | November 17, 2021 | 30/4/2019 | Levocarnitine for Dry Eye in Sjogren's Syndrome | A Randomized Placebo-controlled, Double Blind Pilot Crossover Trial of Levocarnitine for the Treatment of Keratoconjunctivitis Sicca in Sjogren's Syndrome A Randomized Placebo-controlled, Double Blind Pilot Crossover Trial of Levocarnitine for the Treatme ... | Sjogren's Syndrome;Keratoconjunctivitis Sicca | Drug: Levocarnitine;Drug: Placebo | Vanderbilt University Medical Center | NULL | Recruiting | 18 Years | 75 Years | All | 15 | Phase 2 | United States |
| 10 | EUCTR2021-000665-32-DE (EUCTR) | 12/11/2021 | 27/07/2021 | A Study of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) | A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety of Nipocalimab in Adults with Primary Sjogren's Syndrome (pSS) A Randomized, Placebo-controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety ... | Primary Sjogren's Syndrome MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogren's disease;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Immune System Diseases [C20] Primary Sjogren's Syndrome MedDRA version: 21.0;Level: LLT;Classification code 10040766;Term: Sjogre ... | Product Name: Nipocalimab Product Code: M281 INN or Proposed INN: nipocalimab Other descriptive name: JNJ-80202135 Product Name: Nipocalimab Product Code: M281 INN or Proposed INN: nipocalimab Other descriptive name: J ... | Janssen-Cilag International NV | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 150 | Phase 2 | Portugal;France;United States;Taiwan;Spain;Poland;Netherlands;Germany;Italy;Japan |